Abstract: The present invention relates to compounds of formula I: wherein R1, R2, and R3 have the meanings indicated in the specification, which are valuable pharmaceutical active compounds for the therapy and prophylaxis of diseases such as cardiovascular disorders such as high blood pressure, angina pectoris, cardiac insufficiency, thromboses, or atherosclerosis. Compounds of formula I have the ability to modulate the endogenous production of cyclic guanosine monophosphate (cGMP) and are generally suitable for the therapy and prophylaxis of disease states which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for the preparation of compounds formula I, methods of therapy and prophylaxis of the designated disease states and for the production of pharmaceuticals therefor, and pharmaceutical compositions which comprise at least one compound of formula I.

Abstract: Compounds of the formula I in which R1, R2, R3 and Ar have the meanings indicated in the claims, are suitable for the production of pharmaceuticals, for example for the prophylaxis and therapy of cardiovascular diseases such as high blood pressure, angina pectoris, cardiac insufficiency, thromboses or atherosclerosis. The compounds of the formula I have the ability to modulate the endogenous production of cyclic guanosine monophosphate (cGMP) and are generally suitable for the therapy and prophylaxis of disease states which are associated with a disturbed cGMP balance.

Abstract: The present invention relates to pyrazole derivatives of the formula I, their preparation and their use in pharmaceuticals: 1

Abstract: The present invention relates to acylated indanyl amines according to the general formula (I) 1

Abstract: The present invention relates to compounds of the formula I 1

Abstract: The present invention relates to compounds of the formula I wherein A1, A2, R1, R2, R3, X and n are as defined in the claims, which are valuable pharmaceutically active compounds for the therapy and prophylaxis of diseases, for example of cardiovascular diseases such as hypertension, angina pectoris, cardiac insufficiency, thromboses or atherosclerosis. The compounds of the formula I are capable of modulating the body's production of cyclic guanosine monophosphate (cGMP) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of the formula I, to their use for the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of the formula I.

Abstract: The present invention relates to pyrazole derivatives of the formula I, their preparation and their use in pharmaceuticals: ##STR1## in which X, R.sup.1, R.sup.1a, R.sup.2, R.sup.3, R.sup.4 and n are as defined in the claims, which are useful pharmaceutically active compounds for the therapy and prophylaxis of illnesses, for example of cardiovascular diseases such as hypertension, angina pectoris, cardiac insufficiency, thromboses or atherosclerosis. The compounds of the formula I are capable of modulating the body's production of cyclic guanosine monophosphate "cGMP" and are generally suitable for the therapy and prophylaxis of illnesses which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of the formula 1, to their use for the therapy and prophylaxis of the abovementioned illnesses and for preparing pharmaceuticals for this purpose, and also to pharmaceutical preparations which comprise the compounds of the formula I.

Abstract: The invention relates to the use of 2-(N-(2-aminoethyl)amino)acetic acid derivatives of the formula I ##STR1## in which R denotes, for example, phenyl or thienyl, and their pharmacologically acceptable acid addition salts as pharmacological active compounds.

Abstract: The invention relates to the use of 2-(N-(2-aminoethyl)amino)acetic acid derivatives of the formula I ##STR1## in which R denotes, for example, phenyl or thienyl, and their pharmacologically acceptable acid addition salts as pharmacological active compounds.

Abstract: The present invention relates to hydroxymethylfurazancarboxylic acid derivatives of the general formula I ##STR1## in which one of the radicals R.sup.1 and R.sup.2 represents hydroxymethyl and the other represents ##STR2## where X represents NR.sup.3 R.sup.4, OH or OR.sup.7, and R.sup.3, R.sup.4 and R.sup.7 are defined as indicated in claim 1, to processes for their preparation and to their use.

Abstract: The present invention relates to phenyl-1,2,5-oxadiazolecarboxamide-2-oxides of the general formula I ##STR1## in which one of the radicals R.sup.1 and R.sup.2 represents ##STR2## and the other represents ##STR3## and R.sup.3 and R.sup.4 are defined as indicated in claim 1, to processes for their preparation and to their use for the treatment of disorders of the cardiovascular system, including angina pectoris and erectile dysfunctions.

Abstract: The present invention relates to 3-(cis-2,6-dimethylpiperidino)sydnone imine salts of the general formula I ##STR1## in which X denotes H.sub.2 PO.sub.4 or ##STR2## processes for their preparation and their use.

Abstract: The present invention relates to phenylfuroxans of the general formula I ##STR1## in which one of the radicals R.sup.1 and R.sup.2 represents phenyl and the other represents ##STR2## where R.sup.3, R.sup.4 and n are defined as indicated in claim 1, processes for their preparation and their use.

Abstract: The present invention relates to pyrimidofuroxans of the general formula I ##STR1## in which A denotes ##STR2## where in each case the nitrogen atom is bonded via the C-4 and the carbon atom via the C-3 of the furoxan ring and the R radicals are defined as indicated in Claim 1, processes for their preparation and their use for the control and prevention of disorders of the cardiovascular system, in particular for the control and prevention of angina pectoris, and for the treatment of erectile dysfunctions.

Abstract: The present invention relates to pyridyl-1,2,5-oxadiazolcarboxamide-2-oxides of the general formula I ##STR1## in which one of the radicals R.sup.1 and R.sup.2 represents pyridyl and the other represents ##STR2## and R.sup.3 and R.sup.4 are defined as indicated in claim 1, processes for their preparation and their use.

Abstract: The present invention relates to fused 1,2,5-oxadiazole-2-oxides of the general formula I ##STR1## in which A denotes ##STR2## and X, Y, Z as well as R.sup.1, R.sup.2, R.sup.3 and n are defined as indicated in Claim 1, to processes for their preparation and to their use for the control and prevention of disorders of the cardiovascular system, in particular for the control and prevention of angina pectoris, and for the treatment of erectile dysfunctions.

Abstract: Substituted 3-aminosydnonimines of the formula I ##STR1## and pharmacologically acceptable acid addition salts thereof, in which R.sup.1 denotes hydrogen or the radical --COR.sup.4,R.sup.2 denotes alkyl or phenyl alkyl having 1 to 4 C atoms in the alkyl group,R.sup.4 denotes, for example, an aryl radical, and processes and formulations for controlling or preventing cardiovascular diseases by administering an effective amount of such compounds to a host in need thereof.

Abstract: The invention relates to pharmacologically active substituted 3-aminosydnone imines of the general formula I ##STR1## in which n denotes 0 or 1, and their pharmacologically acceptable salts and acid addition salts, and to a process for the preparation of the compounds according to the invention and their use.

Abstract: There are disclosed novel compounds of the formula ##STR1## where X is hydrogen, loweralkyl, loweralkoxy, hydroxy, halogen, nitro or trifluoromethyl; R.sub.1 is hydrogen or loweralkyl; R.sub.2 is hydrogen, loweralkyl, arylloweralkyl or --(CH.sub.2).sub.m R.sub.7 wherein m is 1, 2 or 3 and R.sub.7 is cyano or amino; R.sub.3 and R.sub.4 are independently hydrogen or loweralkyl; R.sub.5 and R.sub.6 are independently hydrogen or loweralkyl, or R.sub.5 +R.sub.6 taken together with the carbon atom to which they are attached constitute a cyclobutane, cyclopentane, cyclohexane, cycloheptane, pyrrolidine, piperidine, morpholine or thiomorpholine ring, or R.sub.5 is hydrogen and R.sub.6 is aryl or --CH.sub.2 OR.sub.8 wherein R.sub.8 is hydrogen, loweralkyl or loweralkylcarbonyl, which are useful for enhancing memory.

Abstract: Substituted 3-aminosydnone imines of the formula I ##STR1## and their pharmacologically acceptable acid addition salts, in which R.sup.1 denotes e.g. hydrogen;R.sup.2 denotes e.g. an alkyl radical;at least two of the radicals R.sup.3, R.sup.4, R.sup.5 and R.sup.6 denote alkyl radicals and the others denote hydrogen, are prepared by cyclization of a compound of the formula II ##STR2## and, if appropriate, subsequent acylation, and have useful pharmacological properties.